Lucid Diagnostics to Participate in Upcoming Virtual Summit
Lucid Diagnostics Inc. (NASDAQ: LUCD), a notable name in cancer prevention medical diagnostics, has announced its participation in an important upcoming event—the 2024 Maxim Healthcare Virtual Summit. As a subsidiary of PAVmed Inc. (NASDAQ: PAVM), Lucid continues to make strides in providing innovative solutions dedicated to early cancer detection.
Event Overview
The 2024 Maxim Healthcare Virtual Summit, set for Tuesday, will feature a fireside chat with Lucid's Chief Financial Officer, Dennis McGrath. This session aims to engage with attendees on pertinent cancer prevention topics and the company's ongoing efforts in diagnostics.
Details of Lucid's Participation
The fireside chat is scheduled for 11:30 AM Eastern Time, providing industry insights and updates from the leadership at Lucid. The virtual format allows for broader participation, ensuring a wider audience can learn about advancements in cancer diagnostics.
About Lucid Diagnostics
Lucid Diagnostics is driven by its mission to serve patients suffering from gastroesophageal reflux disease (GERD). This condition increases the risk of developing serious esophageal precancer and cancer. With its groundbreaking diagnostic tools, Lucid aims to prevent cancer and its associated mortality through early detection.
Innovative Diagnostic Tools
Central to Lucid's approach are the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. These tools represent the first of their kind available commercially and are designed to facilitate easier detection of esophageal precancer in at-risk individuals during brief, noninvasive office procedures.
Lucid's Commitment to Transparency
Following the fireside chat, a recording will be made available, reinforcing Lucid's commitment to transparency and public education. Interested parties are encouraged to visit the investor relations section of the company’s website for this and additional information.
Further Company Insights
As Lucid remains active in the medical diagnostics field, staying updated with their latest initiatives and research is vital. Their forward-thinking approach is expected to contribute significantly to improving patient outcomes over time.
Frequently Asked Questions
What is the 2024 Maxim Healthcare Virtual Summit?
The summit is an event aimed at discussing key issues in healthcare, with participation from various industry leaders including Lucid Diagnostics.
Who is representing Lucid Diagnostics at the summit?
Lucid's Chief Financial Officer, Dennis McGrath, will be featured in the fireside chat.
What is the focus of Lucid Diagnostics?
Lucid Diagnostics focuses on cancer prevention, specifically targeting patients with gastroesophageal reflux disease to prevent esophageal precancer and cancer through early detection.
How can I access the recording of the fireside chat?
The recording will be made available on Lucid's investor relations website post-event.
What innovative solutions does Lucid provide?
Lucid offers the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, designed for noninvasive cancer detection.